Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
The employee options carry a $8.27 exercise price and vest over four years, subject to continuous employment.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Olema Oncology (OLMA) granted six new employees stock options covering 235,950 common shares, effective October 1, 2026, as employment inducements.
The options have an $8.27 per-share exercise price, equal to the last reported Nasdaq sale price on October 1, and a 10-year term. They vest over four years: 25 percent on each employee's first vesting anniversary, followed by 36 equal monthly installments, subject to continuous employment. The Compensation Committee approved the awards under the company's 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Positive
- None.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.235,950 common shares underlying new employee options create potential dilution upon exercise at $8.27 per share.
Key Figures
- Options granted
- 235,950 shares
- Aggregate award to new employees
- Recipients
- 6 employees
- New employees receiving options
- Exercise price
- $8.27 per share
- Equal to the October 1 reported sale price
- Vesting period
- 4 years
- Subject to continued employment
- Initial vesting
- 25%
- Vests on the first anniversary of the employee’s vesting commencement date
- Remaining vesting installments
- 36 equal monthly installments
- Following the first-anniversary vesting
- Option term
- 10 years
- Term of the stock options
Historical Context
-
Granted the CFO options under the 2022 Inducement Plan with four-year vesting.
-
Granted options to seven new employees under the same plan with four-year vesting.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to six new employees to purchase an aggregate of 235,950 shares of the Company's common stock, effective as of October 1, 2026. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of
Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.
Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many stock options did Olema Oncology grant to new employees?
Olema granted six new employees options to purchase an aggregate of 235,950 common shares, effective October 1, 2026. The options have a $8.27 per-share exercise price and a 10-year term.
What is the vesting schedule for Olema Oncology's October 2026 inducement options?
The options vest over four years, with 25 percent vesting on each employee's first vesting anniversary and the remainder in 36 equal monthly installments over the following three years. Vesting requires continuous employment with Olema on each vesting date.